A study of clinical profile, sputum microbiology, and laboratory parameters of patients admitted with acute exacerbation of chronic obstructive pulmonary diseases in rural-based hospital

一项针对农村医院收治的慢性阻塞性肺疾病急性加重患者的临床特征、痰液微生物学和实验室参数的研究

阅读:1

Abstract

BACKGROUND: Acute exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) can increase morbidity and mortality significantly. Patients with AECOPD frequently present with worsening symptoms and deranged laboratory parameters. Bacterial infections in such patients are very common. AIM AND OBJECTIVES: To study and find out the relation between the clinical profile, sputum microbiology, and laboratory parameters of patients with AECOPD. MATERIALS AND METHODS: This was a cross-sectional study conducted on 150 patients admitted with AECOPD from January 2021 to December 2023. RESULTS: Breathlessness was the commonest presenting symptom (100%), followed by productive cough (85.33%) and fever (78.66%). Mean white blood cell count (WBC) was 13,832/cmm(3), which was raised in 87% of patients. Mean C-reactive protein (CRP) was 88.3, which was raised in 89% of patients, whereas the mean procalcitonin (PCT) was 1.05, which was on the higher side in 90% of patients. Sputum analysis revealed Gram-negative bacteria being isolated more, and Pseudomonas aeruginosa (38.33%) and Klebsiella pneumoniae (20%) were the predominant pathogens. Aminoglycosides (amikacin) were sensitive in 91%, followed by carbapenem (meropenem) in 87%, fluoroquinolones (levofloxacin), and penicillin with beta-lactamase inhibitor (piperacillin-tazobactum) were sensitive in 78%, and cephalosporins with beta-lactamase inhibitor (cefoperazone-sulbactam) were sensitive in 69% of patients. CONCLUSION: Clinical findings and laboratory parameters of hospitalized patients of AECOPD suggested bacterial infections are common in AECOPD. Clinical parameters can be good predictors to start the treatment without waiting for culture and investigations. Data on sputum culture and antibiogram of such loco regional study will help to select and start antibiotics as early as possible in AECOPD.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。